ALZ 801

Drug Profile

ALZ 801

Alternative Names: ALZ-801; BLU-8499; NRM-8499; Tramiprosate prodrug

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BELLUS Health
  • Developer Alzheon; BELLUS Health
  • Class Alkanesulfonic-acids; Antidementias; Neuroprotectants; Propylamines; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In volunteers) in Canada (PO, Capsule)
  • 24 Oct 2017 ALZ 801 receives Fast Track designation for Alzheimer's disease [PO] (In adolescents, In adults) in USA
  • 20 Sep 2017 Alzheon plans a phase III pivotal trial for Alzheimer's disease (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top